Alamar Biosciences reported a 99% increase in revenue for Q1 2026, reaching $26 million driven by strong sales of instruments and consumables. The company launched two new neurodegenerative disease research products and completed a successful IPO in April 2026, raising approximately $220 million in gross proceeds. Despite higher operating expenses and a net loss of $21.3 million, Alamar's strengthened balance sheet positions it to accelerate adoption of its Precision Proteomics platform. Full-year 2026 revenue guidance will be provided with the Q2 earnings report in August.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
Ecopetrol, Colombia's largest energy company, will announce its financial and operating results for the second quarter of 2026 on August 3 after market close. A virtual conference will follow on August 4, featuring simultaneous Spanish and English br...
Galaxy Digital reports that large Bitcoin holders (whales) have not sold their holdings over fears of quantum computing risks. Instead, concerns about quantum threats seem to influence institutional investors who are hesitant to buy Bitcoin. Recent l...
Visionstate Corp. has decided to pause its previously announced non-brokered private placement financing under the LIFE exemption, initially targeting $500,000 to $1,000,000. The company will use this time to reconsider the structure and timing of th...
